

## Oxlumo™(lumasiran) (Subcutaneous)

---

**Effective Date:** 4/1/2021

**Review Date:** 3/11/2021

**Revision date:** 3/11/2021

**Scope:** Medicaid, Commercial, Medicare-Medicaid Plan (MMP)

### I. Length of Authorization

Coverage will be provided for 6 months initially and may be renewed annually thereafter.

### II. Dosing Limits

#### A. Quantity Limit (max daily dose) [NDC Unit]:

- Oxlumo 94.5 mg/0.5 mL in a single-dose vial for injection: 4 vials every month for 3 doses then every 3 months thereafter

#### B. Max Units (per dose and over time) [HCPS Unit]:

- 345 mg every month for 3 doses then every 3 months thereafter

### III. Initial Approval Criteria

Coverage is provided in the following conditions:

MMP members who have previously received this medication within the past 365 days are not subject to Step Therapy Requirements

Universal Criteria <sup>1,2,3,4</sup>

- Patient has not had a kidney or liver transplant; AND
- Must be prescribed by, or in consultation with, a specialist in genetics, nephrology or urology; AND

#### Primary Hyperoxaluria type 1 (PH1) † Φ <sup>1,2</sup>

- Patient has a definitive diagnosis of primary hyperoxaluria type 1 as evidenced by one of the following:
  - Patient has a biallelic pathogenic mutation in the alanine:glyoxylate aminotransferase (AGXT) gene as identified on molecular genetic testing; OR
  - Identification of alanine:glyoxylate aminotransferase (AGT) enzyme deficiency on liver biopsy; AND
- Patient has an eGFR  $\geq 30$  mL/min/1.73 m<sup>2</sup>; AND

- Patient does not have clinical evidence of systemic oxalosis; AND
- Documentation that the patient has made efforts to increase fluid intake to at least 3 L/m<sup>2</sup> BSA per day; AND
- Concurrent use of pyridoxine OR previous trial of at least 3 months of pyridoxine with no significant improvement observed (e.g. <30% reduction in urine oxalate concentration after at least 3 months of therapy); AND
- Patient has a baseline for one or more of the following:
  - Urinary oxalate excretion level (corrected for BSA)
  - Spot urinary oxalate:creatinine ratio
  - Estimated glomerular filtration rate (eGFR)

† FDA Approved Indication(s); ‡ Compendium Recommended Indication(s); Φ Orphan Drug

#### IV. **Renewal Criteria** <sup>1</sup>

Coverage can be renewed based upon the following criteria:

- Patient continues to meet the universal and other indication-specific relevant criteria identified in section III; AND
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include severe injection site reactions, etc.; AND
- Disease response as evidenced by one or more of the following: a decrease in urinary oxalate excretion from baseline, a reduction in spot urinary oxalate: creatinine ratio from baseline, and/or stabilization of glomerular filtration rate.

#### V. **Dosage/Administration**

Indication	Dose		
Primary Hyperoxaluria type 1 (PH1)	Actual Body Weight	Loading Dose	Maintenance dose
	Less than 10kg	6mg/kg once a month for 3 doses	3mg/kg once monthly
	10kg to less than 20kg	6mg/kg once a month for 3 doses	6mg/kg once every 3 months
	20 kg and above	3mg/kg once a month for 3 doses	3mg/kg once every 3 months
	Note: Begin maintenance doses 1 month after the last loading dose		

## VI. Billing Code/Availability Information

### HCPCS:

- J3490 – Unclassified drugs

### NDC:

- Oxlumio 94.5 mg/0.5 mL in a single-dose vial solution for injection: 71336-1002-xx

## VII. References

1. Oxlumio [package insert]. Cambridge, MA; Alnylam Pharm., Inc., November 2020. Accessed November 2020.
2. Milliner DS, Harris PC, Cogal AG, et al. Primary Hyperoxaluria Type 1. <https://www.ncbi.nlm.nih.gov/books/NBK1283/>. (Accessed on November 25, 2020).
3. Alnylam Pharmaceuticals. ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1. Available from: <https://clinicaltrials.gov/ct2/show/NCT03681184?term=NCT03681184&draw=2&rank=1>. Accessed November 25, 2020.
4. Alnylam Pharmaceuticals. ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1. Available from: <https://clinicaltrials.gov/ct2/show/NCT03905694?term=NCT03905694&draw=2&rank=1>. Accessed November 25, 2020.

## Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
E72.53	Primary hyperoxaluria

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Articles (LCAs) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCA/LCD): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC